Literature DB >> 8239604

Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin.

D Landman1, N K Mobarakai, J M Quale.   

Abstract

Enterococci have emerged as significant nosocomial pathogens. Enterococci with resistance to commonly used antibiotics are appearing more frequently. We encountered at our institution several infections caused by Enterococcus faecium with high-level resistance to ampicillin, vancomycin, and gentamicin. The optimal antibiotic therapy for serious infections with unusually resistant enterococci has not been established. Using time-kill studies, we tested the effectiveness of various antibiotic combinations against 15 isolates of multidrug-resistant enterococci. No antibiotic was consistently effective when used alone. The combination of ampicillin plus ciprofloxacin was bactericidal for the 12 isolates for which the ciprofloxacin MIC was < or = 8 micrograms/ml. The combination of ciprofloxacin plus novobiocin also demonstrated activity against these isolates. No combination was found to be bactericidal for the remaining three isolates, which were highly ciprofloxacin resistant. These antibiotic combinations may be important for the future treatment of serious infections caused by these resistant pathogens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239604      PMCID: PMC188090          DOI: 10.1128/AAC.37.9.1904

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Identification of Enterococcus species isolated from human infections by a conventional test scheme.

Authors:  R R Facklam; M D Collins
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

2.  The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.

Authors:  K Muranaka; D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

3.  Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin.

Authors:  J E Patterson; S M Colodny; M J Zervos
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

4.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

5.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate.

Authors:  M K Hayden; G M Trenholme; J E Schultz; D F Sahm
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

7.  Inducible resistance to vancomycin in Enterococcus faecium D366.

Authors:  R Williamson; S Al-Obeid; J H Shlaes; F W Goldstein; D M Shlaes
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

8.  Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.

Authors:  D M Shlaes; A Bouvet; C Devine; J H Shlaes; S al-Obeid; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

9.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis.

Authors:  M Fernandez-Guerrero; M S Rouse; N K Henry; J E Geraci; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  13 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.

Authors:  S Bratu; J Quale; S Cebular; R Heddurshetti; D Landman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

5.  Synthesis and evaluation of 1,2,4-triazolo[1,5-a]pyrimidines as antibacterial agents against Enterococcus faecium.

Authors:  Huan Wang; Mijoon Lee; Zhihong Peng; Blas Blázquez; Elena Lastochkin; Malika Kumarasiri; Renee Bouley; Mayland Chang; Shahriar Mobashery
Journal:  J Med Chem       Date:  2015-05-12       Impact factor: 7.446

6.  Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  Epidemiol Infect       Date:  2010-08-09       Impact factor: 2.451

7.  Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.

Authors:  S Burney; D Landman; J M Quale
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 8.  Multidrug-resistant enterococci: the dawn of a new era in resistant pathogens.

Authors:  S J Antony
Journal:  J Natl Med Assoc       Date:  1998-09       Impact factor: 1.798

Review 9.  Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen.

Authors:  R V Spera; B F Farber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

10.  Molecular & phenotypic characterization of Staphylococcus epidermidis in implant related infections.

Authors:  Sujata Prasad; N Nayak; G Satpathy; H L Nag; P Venkatesh; S Ramakrishnan; Supriyo Ghose; T C Nag
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.